Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
H
Hongwei Xu
Role not yet determined Is this you? Add your title
Also affiliated: Winthrop Rockefeller Foundation (2022–2025); Arkansas Children's Nutrition Center (2025)
2 h-index
13 pubs
33 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Hongwei Xu's research focuses on the molecular mechanisms underlying various diseases, with a particular emphasis on cancer and immune system function. His work has investigated the role of extracellular vesicles and microRNAs in disease progression, as well as the development of novel therapeutic strategies for conditions like multiple myeloma and hepatocellular carcinoma. Xu has published on the modulation of protein deubiquitination in B cell malignancies and the potential of bispecific CAR-T cells for controlling myeloma growth. His research also extends to diagnostic applications, such as the development of ultrasensitive detection systems for microRNAs in esophageal cancer serum and the evaluation of serum pepsinogen levels for gastric cancer screening. Xu collaborates with researchers at the University of Arkansas for Medical Sciences, including David E. Mery, Visanu Wanchai, Fenghuang Zhan, and Fumou Sun, with whom he has co-authored multiple publications.
Metrics
- h-index: 2
- Publications: 13
- Citations: 33
Selected Publications
-
Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Abstract 860: BCMA CAR-T cells releasing mutant CST6 N137D proteins further improve therapeutic effects in multiple myeloma (2025)
-
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)
-
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)
-
Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression (2024)
-
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)
-
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)
-
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024)
-
The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx (2024)
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)
Collaboration Network
Top Collaborators
John D. Shaughnessy
Winthrop Rockefeller Foundation
22 shared publications
In database
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- RARα2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
- Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
Showing 5 of 22 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
20 shared publications
In database
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Showing 5 of 20 shared publications
Guido Tricot
University of Arkansas for Medical Sciences
18 shared publications
In database
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- RARα2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
- Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 18 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
17 shared publications
In database
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- RARα2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Showing 5 of 17 shared publications
Fenghuang Zhan
University of Arkansas for Medical Sciences
17 shared publications
In database
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
- The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
- Macrophages: A communication network linking Porphyromonas gingivalis infection and associated systemic diseases
- RARα2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
- Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
Showing 5 of 17 shared publications
Fumou Sun
Medical College of Wisconsin
16 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 16 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
14 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 14 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
14 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 14 shared publications
Yan Cheng
Winthrop Rockefeller Foundation
13 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Showing 5 of 13 shared publications
David E. Mery
University of Arkansas for Medical Sciences
13 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 13 shared publications
Samer Al Hadidi
University of Arkansas for Medical Sciences
13 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 13 shared publications
Clyde Bailey
University of Arkansas for Medical Sciences
12 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
Showing 5 of 12 shared publications
Dongzheng Gai
Winthrop Rockefeller Foundation
11 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions
Showing 5 of 11 shared publications
Fenghuang Zhan
Winthrop Rockefeller Foundation
11 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
- Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
Showing 5 of 11 shared publications
Eric R. Siegel
University of Arkansas for Medical Sciences
10 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages
Showing 5 of 10 shared publications
Similar Researchers
Based on overlapping research topics
Jacob L Edmondson
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Ryan M. Allen
University of Arkansas for Medical Sciences
Extracellular vesicles in disease
MicroRNA in disease regulation
Cancer Treatment and Pharmacology
Cade Richesin
University of Arkansas at Fayetteville
Cancer-related molecular mechanisms research
Immune Response and Inflammation
CAR-T cell therapy research
Ahmad Mazen Safar
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
lan J Tackett
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Rajshekar A. Kore
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Immune Response and Inflammation
Disease Mechanisms Research